In contrast to some other immune-regulated tumors that are involved in tumor infiltration along with CD8 T cells, which could drive the response to anti-PD-1 therapy, the role of CD8 T cells in response to ICIs in ccRCC remains unclear. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.